Multiple mechanisms have in fact been shown to increase Telomerase activity in hematological malignancies (e.g. epigenetic modulation, amplification of the hTERT gene), thus suggesting that TERT may represent an optimal target for human DLBCL [25]. This evidence concerns the gene TERT and diffuse large B-cell lymphoma.